Latest Biotech News

Recursion delivered a phenotypic microglia map to Roche/Genentech under a collaboration and received a $30 million milestone payment, the latest tranche in a multi‑hundred‑million dollar...

10x Genomics introduced a next‑generation Chromium Flex assay that supports automation‑compatible plate‑based multiplexing of up to 384 samples, enabling profiling at scales the company says can...

Thermo Fisher Scientific agreed to acquire Clario in a cash deal that pays roughly $8.9 billion upfront plus contingent consideration, valuing the clinical-trial data and software specialist at up...

The U.S. Food and Drug Administration published draft guidance aiming to streamline biosimilar approvals by no longer routinely requiring head‑to‑head clinical efficacy studies against branded...

Novartis agreed to acquire Avidity Biosciences for about $12 billion to secure three RNA‑based therapies in pivotal testing and Avidity’s delivery platform that aims to expand RNA therapeutics...

Eli Lilly and Nvidia announced a partnership to build what they describe as the most powerful supercomputer owned by a pharmaceutical company, aimed at training larger AI models for drug...

BridgeBio Pharma reported positive top‑line results from a global Phase III trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The company said 76% of treated patients met...

Recursion announced delivery of a whole‑genome microglia phenomap to Roche and Genentech under their multi‑year AI partnership, prompting a $30 million milestone payment and lifting total...

10x Genomics unveiled the next generation of its Chromium Flex assay: an automation‑compatible, plate‑based workflow that enables 384‑sample multiplexing and the capacity to process up to 100...

iOrganBio emerged from stealth with $2 million in seed funding and introduced CellForge, an AI‑driven cell manufacturing platform aimed at producing predictable, reproducible human cells and...

Kyverna Therapeutics reported positive Phase II data for KYV‑101, a fully human, autologous CD19 CAR‑T with CD28 co‑stimulation, in generalized myasthenia gravis (gMG). In the Phase II portion of...

GSK inked an exclusive license with Empirico for a Phase I siRNA candidate, EMP‑012, focused on chronic obstructive pulmonary disease and other inflammatory respiratory diseases. The deal carries...

Intellia Therapeutics halted enrollment and dosing in two clinical trials of its in vivo CRISPR candidate, nex‑z, after a patient was hospitalized with liver toxicity. The company notified...

Novartis agreed to acquire Avidity Biosciences for about $12 billion to gain three late‑stage antibody‑oligonucleotide conjugates (AOCs) focused on neuromuscular diseases. The deal adds delivery...

Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase III, single‑dose AAV gene therapy for wet age‑related macular degeneration (wAMD). Lilly said...

Merck reported positive results from two large trials of Welireg in renal cell carcinoma, outcomes that could expand use of the oral kinase inhibitor across kidney cancer populations. The data...

BridgeBio reported multiple late‑stage successes this week: encaleret met primary and key secondary endpoints in autosomal dominant hypocalcemia type 1 (ADH1), normalizing calcium and urine...

Kyverna Therapeutics reported Phase 2 data for KYV‑101, a CD19 CAR‑T regimen, showing clinical responses in a small cohort of generalized myasthenia gravis (gMG) patients. Six treated patients...

Recursion provided Roche and Genentech with a whole‑genome microglia phenomap derived from a massive imaging perturbation set; Roche triggered a $30 million milestone payment that lifted total...

Regeneron expanded its multispecific antibody capabilities via a strategic collaboration with ModeX Therapeutics. The agreement includes a modest upfront payment and potential development,...